SUPPLEMENT

Q1 2024 — Financial disclosures

Q1 2024PDF · 9 pages1.0 MB
Merck & Co., Inc.
Financial Highlights Package
First Quarter 2024
Table of Contents
Table 1: 	GAAP P&L..........................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter......2
Table 2a: GAAP to Non-GAAP Reconciliation 1Q24.........................3
Table 2b: GAAP to Non-GAAP Reconciliation 1Q23.........................4
Table 3: Sales – Current Year and Prior Year by Quarter ...............5
Table 3a: Sales – U.S. / Ex- U.S. 1Q24.............................................6
Table 3b: Sales – Pharmaceutical Geographic Split .........................7
Table 4: Other (Income) Expense ....................................................8

-- 1 of 9 --

Sales 	15,775	$ 	14,487	$ 	9%
Costs, Expenses and Other
Cost of sales 	3,540 	3,926 	-10%
Selling, general and administrative 	2,483 	2,479 	0%
Research and development 	3,992 	4,276 	-7%
Restructuring costs 	123 	67 	84%
Other (income) expense, net 	(33) 	89 	*
Income Before Taxes 	5,670 	3,650 	55%
Income Tax Provision 	903 	825
Net Income 	4,767 	2,825 	69%
Less: Net Income Attributable to Noncontrolling Interests 	5 	4
Net Income Attributable to Merck & Co., Inc. 	4,762	$ 	2,821	$ 	69%
Earnings per Common Share Assuming Dilution 	1.87	$ 	1.11	$ 	68%
Average Shares Outstanding Assuming Dilution 	2,544 	2,551
Tax Rate 	15.9% 	22.6%
* 100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
1Q24 	1Q23
1

-- 2 of 9 --

Sales 	15,775	$ 	14,487	$ 	15,035	$ 	15,962	$ 	14,630	$ 	60,115	$ 	9%
Costs, Expenses and Other
Cost of sales 	3,540 	3,926 	4,024 	4,264 	3,911 	16,126 	-10%
Selling, general and administrative 	2,483 	2,479 	2,702 	2,519 	2,804 	10,504 	0%
Research and development 	3,992 	4,276 	13,321 	3,307 	9,628 	30,531 	-7%
Restructuring costs 	123 	67 	151 	126 	255 	599 	84%
Other (income) expense, net 	(33) 	89 	172 	126 	78 	466 	*
Income (Loss) Before Taxes 	5,670 	3,650 	(5,335) 	5,620 	(2,046) 	1,889 	55%
Income Tax Provision (Benefit) 	903 	825 	637 	870 	(821) 	1,512
Net Income (Loss) 	4,767 	2,825 	(5,972) 	4,750 	(1,225) 	377 	69%
Less: Net Income Attributable to Noncontrolling Interests 	5 	4 	3 	5 	1 	12
Net Income (Loss) Attributable to Merck & Co., Inc. 	4,762	$ 	2,821	$ 	(5,975)	$ 	4,745	$ 	(1,226)	$ 	365	$ 	69%
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.87	$ 	1.11	$ 	(2.35)	$ 	1.86	$ 	(0.48)	$ 	0.14	$ 	68%
Average Shares Outstanding Assuming Dilution (1) 	2,544 	2,551 	2,539 	2,546 	2,533 	2,547
Tax Rate 	15.9% 	22.6% 	-11.9% 	15.5% 	40.1% 	80.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
%
Change
1Q
(1) Because the company recorded a net loss in the second and fourth quarters of 2023, no potential dilutive common shares were used in the computation of
loss per common share assuming dilution as the effect would have been anti-dilutive.
2024
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2023
2

-- 3 of 9 --

First Quarter
Cost of sales 	3,540	$ 	463 	116 	579 	2,961	$
Selling, general and administrative 	2,483 	21 	5 	26 	2,457
Research and development 	3,992 	16 	2 	18 	3,974
Restructuring costs 	123 	123 	123 	–
Other (income) expense, net 	(33) 	(4) 	(116) 	(120) 	87
Income Before Taxes 	5,670 	(496) 	(246) 	116 	(626) 	6,296
Income Tax Provision (Benefit) 	903 	(92) (3) 	(42) (3) 	25 (3) 	(109) 	1,012
Net Income 	4,767 	(404) 	(204) 	91 	(517) 	5,284
Net Income Attributable to Merck & Co., Inc. 	4,762 	(404) 	(204) 	91 	(517) 	5,279
Earnings per Common Share Assuming Dilution 	1.87	$ 	(0.16) 	(0.08) 	0.04 	(0.20) 	2.07	$
Tax Rate 	15.9% 	16.1%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
FIRST QUARTER 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Table 2a
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP
measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s
compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in
accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other
costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, primarily
reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
3

-- 4 of 9 --

First Quarter
Cost of sales 	3,926	$ 	545 	29 	574 	3,352	$
Selling, general and administrative 	2,479 	20 	1 	21 	2,458
Research and development 	4,276 	10 	10 	4,266
Restructuring costs 	67 	67 	67 	-
Other (income) expense, net 	89 	15 	(429) 	573 (3) 	159 	(70)
Income Before Taxes 	3,650 	(590) 	(97) 	429 	(573) 	(831) 	4,481
Income Tax Provision (Benefit) 	825 	(105) (4) 	(18) (4) 	95 (4) 	(60) (4) 	(88) 	913
Net Income 	2,825 	(485) 	(79) 	334 	(513) 	(743) 	3,568
Net Income Attributable to Merck & Co., Inc. 	2,821 	(485) 	(79) 	334 	(513) 	(743) 	3,564
Earnings per Common Share Assuming Dilution 	1.11	$ 	(0.19) 	(0.03) 	0.13 	(0.20) 	(0.29) 	1.40	$
Tax Rate 	22.6% 	20.4%
Only the line items that are affected by non-GAAP adjustments are shown.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
MERCK & CO., INC.
FIRST QUARTER 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures
internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived
in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs
related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Amounts included in other (income) expense, net, reflect a $37 million
loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially offset by royalty
income.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
4

-- 5 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2024 	2023 	1Q
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$15,775 	$14,487 	$15,035 	$15,962 	$14,630 	$60,115 	9 	12
PHARMACEUTICAL 	14,006 	12,721 	13,457 	14,263 	13,141 	53,583 	10 	13
Oncology
Keytruda 	6,947 	5,795 	6,271 	6,338 	6,608 	25,011 	20 	24
Alliance Revenue – Lynparza (2) 	292 	275 	310 	299 	315 	1,199 	6 	7
Alliance Revenue – Lenvima (2) 	255 	232 	242 	260 	226 	960 	10 	10
Welireg 	85 	42 	50 	54 	72 	218 	102 	102
Alliance Revenue – Reblozyl (3) 	71 	43 	47 	52 	70 	212 	66 	66
Vaccines (4)
Gardasil/Gardasil 9 	2,249 	1,972 	2,458 	2,585 	1,871 	8,886 	14 	17
ProQuad/M-M-R II/Varivax 	570 	528 	582 	713 	545 	2,368 	8 	8
Vaxneuvance 	219 	106 	168 	214 	176 	665 	106 	106
RotaTeq 	216 	297 	131 	156 	185 	769 	-27 	-27
Pneumovax 23 	61 	96 	92 	140 	85 	412 	-36 	-33
Hospital Acute Care
Bridion 	440 	487 	502 	424 	429 	1,842 	-10 	-8
Prevymis 	174 	129 	143 	157 	175 	605 	35 	39
Dificid 	73 	65 	76 	74 	87 	302 	12 	12
Zerbaxa 	56 	50 	54 	53 	61 	218 	13 	15
Noxafil 	56 	60 	55 	51 	46 	213 	-7 	4
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	98 	99 	68 	92 	108 	367 	-1 	-1
Adempas (6) 	70 	59 	65 	65 	66 	255 	18 	18
Virology
Lagevrio 	350 	392 	203 	640 	193 	1,428 	-11 	-5
Isentress/Isentress HD 	111 	123 	136 	119 	105 	483 	-10 	-7
Delstrigo 	56 	44 	50 	54 	54 	201 	28 	30
Pifeltro 	42 	34 	38 	37 	33 	142 	23 	23
Neuroscience
Belsomra 	46 	56 	63 	58 	54 	231 	-17 	-11
Immunology
Simponi 	184 	180 	180 	179 	171 	710 	2 	1
Remicade 	39 	51 	48 	45 	43 	187 	-24 	-21
Diabetes (7)
Januvia 	419 	551 	511 	581 	547 	2,189 	-24 	-21
Janumet 	251 	329 	354 	255 	240 	1,177 	-24 	-20
Other Pharmaceutical (8) 	576 	626 	560 	568 	576 	2,333 	-8 	-6
ANIMAL HEALTH 	1,511 	1,491 	1,456 	1,400 	1,278 	5,625 	1 	4
Livestock 	850 	849 	807 	874 	808 	3,337 	- 	4
Companion Animal 	661 	642 	649 	526 	470 	2,288 	3 	4
Other Revenues (9) 	258 	275 	122 	299 	211 	907 	-6 	11
*200% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,424 million in the first quarter of 2024 and $3,133 million in the first quarter 2023.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of
sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $745 million in the first quarter of 2024 and $950 million in the first quarter of 2023.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate
revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed
products were$61 million in the first quarter of 2024 and $51 million in the first quarter of 2023.
5

-- 6 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FIRST QUARTER 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
1Q 2024 	1Q 2023 	% Change 	1Q 2024 	1Q 2023 	% Change 	1Q 2024 	1Q 2023 	% Change
TOTAL SALES (1) 	$15,775 	$14,487 	9 	$7,478 	$6,659 	12 	$8,297 	$7,828 	6
PHARMACEUTICAL 	14,006 	12,721 	10 	6,936 	6,117 	13 	7,070 	6,604 	7
Oncology
Keytruda 	6,947 	5,795 	20 	4,119 	3,485 	18 	2,828 	2,310 	22
Alliance Revenue – Lynparza (2) 	292 	275 	6 	135 	142 	-4 	157 	133 	18
Alliance Revenue – Lenvima (2) 	255 	232 	10 	173 	153 	13 	82 	79 	3
Welireg 	85 	42 	102 	77 	41 	89 	7 	1 	*
Alliance Revenue – Reblozyl (3) 	71 	43 	66 	58 	30 	93 	12 	12 	-
Vaccines (4)
Gardasil/Gardasil 9 	2,249 	1,972 	14 	488 	416 	17 	1,761 	1,556 	13
ProQuad/M-M-R II/Varivax 	570 	528 	8 	438 	421 	4 	133 	107 	24
Vaxneuvance 	219 	106 	106 	161 	94 	72 	58 	13 	*
RotaTeq 	216 	297 	-27 	149 	180 	-17 	67 	117 	-43
Pneumovax 23 	61 	96 	-36 	6 	40 	-85 	55 	56 	-1
Hospital Acute Care
Bridion 	440 	487 	-10 	329 	276 	19 	111 	210 	-47
Prevymis 	174 	129 	35 	74 	54 	37 	100 	75 	33
Dificid 	73 	65 	12 	68 	62 	10 	5 	3 	49
Zerbaxa 	56 	50 	13 	33 	27 	23 	23 	23 	1
Noxafil 	56 	60 	-7 	8 	14 	-43 	48 	46 	4
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	98 	99 	-1 	90 	83 	8 	8 	16 	-51
Adempas (6) 	70 	59 	18 	70 	59 	18
Virology
Lagevrio 	350 	392 	-11 	45 	-2 	* 	305 	394 	-23
Isentress/Isentress HD 	111 	123 	-10 	50 	52 	-3 	61 	71 	-14
Delstrigo 	56 	44 	28 	12 	11 	9 	44 	33 	34
Pifeltro 	42 	34 	23 	29 	24 	22 	13 	10 	25
Neuroscience
Belsomra 	46 	56 	-17 	15 	16 	-9 	32 	40 	-21
Immunology
Simponi 	184 	180 	2 	184 	180 	2
Remicade 	39 	51 	-24 	39 	51 	-24
Diabetes (7)
Januvia 	419 	551 	-24 	183 	271 	-32 	236 	280 	-16
Janumet 	251 	329 	-24 	39 	56 	-32 	212 	272 	-22
Other Pharmaceutical (8) 	576 	626 	-8 	157 	171 	-8 	419 	457 	-8
ANIMAL HEALTH 	1,511 	1,491 	1 	474 	482 	-2 	1,037 	1,010 	3
Livestock 	850 	849 	- 	166 	174 	-5 	683 	676 	1
Companion Animal 	661 	642 	3 	308 	308 	- 	354 	334 	6
Other Revenues (9) 	258 	275 	-6 	68 	60 	13 	190 	214 	-11
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $745 million in the first quarter of 2024 and $950 million in the first quarter of 2023.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $61
million in the first quarter of 2024 and $51 million in the first quarter of 2023.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,424 million in the first quarter of 2024 and $3,133 million in the first quarter 2023.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
6

-- 7 of 9 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
2024 	2023 	% Change
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
TOTAL PHARMACEUTICAL 	$14,006 	$12,721 	$13,457 	$14,263 	$13,141 	$53,583 	10
United States 	6,936 	6,117 	6,570 	7,153 	6,698 	26,539 	13
% Pharmaceutical Sales 	49.5% 	48.1% 	48.8% 	50.1% 	51.0% 	49.5%
Europe (1) 	2,555 	2,326 	2,401 	2,497 	2,491 	9,715 	10
% Pharmaceutical Sales 	18.2% 	18.3% 	17.8% 	17.5% 	19.0% 	18.1%
China 	1,744 	1,694 	1,887 	1,674 	1,456 	6,710 	3
% Pharmaceutical Sales 	12.5% 	13.3% 	14.0% 	11.7% 	11.1% 	12.5%
Japan 	802 	737 	652 	1,062 	629 	3,081 	9
% Pharmaceutical Sales 	5.7% 	5.8% 	4.8% 	7.4% 	4.8% 	5.7%
Latin America 	601 	470 	566 	696 	596 	2,328 	28
% Pharmaceutical Sales 	4.3% 	3.7% 	4.2% 	4.9% 	4.5% 	4.3%
Asia Pacific (other than China and Japan) 	580 	703 	705 	636 	616 	2,661 	-18
% Pharmaceutical Sales 	4.1% 	5.5% 	5.2% 	4.5% 	4.7% 	5.0%
Eastern Europe/Middle East/Africa 	395 	381 	370 	301 	299 	1,351 	3
% Pharmaceutical Sales 	2.8% 	3.0% 	2.7% 	2.1% 	2.3% 	2.5%
Canada 	138 	141 	127 	133 	138 	540 	-2
% Pharmaceutical Sales 	1.0% 	1.1% 	0.9% 	0.9% 	1.1% 	1.0%
Other 	255 	152 	179 	111 	218 	658 	68
% Pharmaceutical Sales 	1.9% 	1.2% 	1.6% 	0.9% 	1.5% 	1.4%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
7

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
1Q24 	1Q23
Interest income 	(73)	$ 	(112)	$
Interest expense 	303 	242
Exchange losses 	83 	61
Income from investments in equity securities, net (1) (143) 	(450)
Net periodic defined benefit plan (credit) cost other than service cost 	(160) 	(115)
Other, net 	(43) 	463
Total 	(33)	$ 	89	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through
ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the
end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter
lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
8

-- 9 of 9 --